

PROXYMED INC /FT LAUDERDALE/

Form 8-K

February 20, 2002

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  
February 14, 2002

**PROXYMED, INC.**

---

(Exact name of registrant as specified in its charter)

<b>Florida</b>	<b>0-22052</b>	<b>65-0202059</b>
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
<b>2555 Davie Road, Suite 110, Ft. Lauderdale, Florida</b>		<b>33317-7424</b>
(Address of principal executive offices)		(Zip Code)

Registrant's telephone number, including area code (954) 473-1001

---

**Item 5. Other Items.**

The Company's press release dated February 13, 2002 reporting financial results for the three months and year ended December 31, 2001 is attached.

**Item 9. Regulation FD Disclosure.**

On February 14, 2002, the ProxyMed, Inc. (the Company ) held a teleconference call to report its financial and operating results for the quarter and year ended December 31, 2001. A transcript of the call, excluding questions from participants and answers from management, is attached.

**FORWARD LOOKING STATEMENTS** This document, including the exhibits attached hereto, contains forward-looking statements that reflect the Company's current assumptions and expectations regarding future events. While these statements reflect the Company's current judgment, they are subject to risks and uncertainties. Actual results may differ significantly from projected results due to a number of factors, including, but not limited to the soundness of our business strategies relative to the perceived market opportunities; our ability to successfully develop, market, sell, cross-sell, install and upgrade our clinical and financial transaction services and applications to current and new physicians, payers, medical laboratories and pharmacies; our ability to consummate and integrate any acquisitions successfully; our ability to compete effectively on price and support services; our assessment of the healthcare industry's need, desire and ability to become technology efficient; and our ability and that of our business associates to comply with various government rules regarding healthcare and patient privacy. These and other risk factors are more fully discussed in our filings with the Securities and Exchange Commission, which we strongly urge you to read. ProxyMed expressly disclaims any intent or obligation to update any forward-looking statements. When used, the words believes, estimated, expects, anticipates, may and similar expressions are intended to identify forward-looking statements.

**Item 7. Financial Statements and Exhibits.**

(c) The following exhibits are included herein:

- |              |  |
|--------------|--|
| Exhibit 99.1 | Transcript of fourth quarter and year end 2001 financial results teleconference call held on February 14, 2002.          |
| Exhibit 99.2 | Press Release dated February 13, 2002 reporting financial results for the three months and year ended December 31, 2001. |

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ProxyMed, Inc.**

Date: February 20, 2002 \_\_\_\_\_

/s/ Judson E. Schmid  
\_\_\_\_\_

Judson E. Schmid, Executive Vice  
President and Chief Financial Officer

INDEX TO EXHIBITS

**EXHIBIT NUMBER**

---

**DESCRIPTION**

---

99.1	Transcript of fourth quarter and year end 2001 financial results teleconference call held on February 14, 2002.
99.2	Press Release dated February 13, 2002 reporting financial results for the three month and year ended December 31, 2001.